14 June 2021

Amedeo Smart

Independent Medical Education

Subscriber: th..@boehringer-ingelheim.com

HIV Infection

14 June 2021 | n=70

  1. Nwogu JN, Gandhi M, Owen A, Khoo S, et al.
    Associations between efavirenz concentrations, pharmacogenetics, and neurocognitive performance in people living with HIV in Nigeria.
    AIDS 2021.

  2. Rolle CP, Berhe M, Singh T, Ortiz R, et al.
    Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV.
    AIDS 2021.

  3. Heath K, Levi J, Hill A.
    Reaching UNAIDS 95-95-95 targets worldwide: predicted benefits and treatment costs with generic manufacture.
    AIDS 2021.

  4. Robertson J, Eden A, Nystrom K, Hagberg L, et al.
    Increased immune activation and signs of neuronal injury in HIV-negative people on pre-exposure prophylaxis (PrEP).
    AIDS 2021.

  5. Koehn K, Cassidy-Matthews C, Pearce M, Aspin C, et al.
    Rates of new HIV diagnoses among Indigenous peoples in Canada, Australia, New Zealand, and the United States: 2009-2017.
    AIDS 2021.

  6. Genberg BL, Wilson-Barthes MG, Omodi V, Hogan JW, et al.
    Microfinance, retention in care, and mortality among patients enrolled in HIV 2 Care in East Africa.
    AIDS 2021.

  7. Claytor JD, Viramontes O, Conner S, Wen KW, et al.
    TNF-alpha inhibition in the setting of undiagnosed HIV infection: a call for enhanced screening guidelines.
    AIDS 2021.

  8. Nduati EW, Gorman MJ, Sein Y, Hermanus T, et al.
    Coordinated Fc-effector and neutralization functions in HIV-infected children define a window of opportunity for HIV vaccination.
    AIDS 2021.

  9. Guardigni V, Toschi A, Badia L, Del Turco ER, et al.
    Patients living with HIV and cirrhosis: the risk for hepatocellular carcinoma after direct-acting antivirals for HCV.
    AIDS 2021.

  10. Jin F, Amin J, Guy R, Vaccher S, et al.
    Adherence to daily HIV Pre-exposure prophylaxis in a large-scale implementation study in New South Wales, Australia.
    AIDS 2021.

  11. Makadzange TA, Hlupeni A, Machekano R, Boyd K, et al.
    Survival following screening and preemptive antifungal therapy for subclinical cryptococcal disease in advanced HIV infection.
    AIDS 2021.

  12. Gabriel EM, Salinas TRW, Gosselin A, Larouche-Anctil E, et al.
    Overt IL-32 Isoform Expression at Intestinal Level during HIV-1 Infection is Negatively Regulated by IL-17A.
    AIDS 2021.

  13. Herrera C, Harman S, Aldon Y, Rogers P, et al.
    The entry inhibitor DS003 (BMS-599793), a BMS-806 analogue, provides superior activity as a pre-exposure prophylaxis candidate.
    AIDS 2021.

  14. MacPhail AI, McLean C, Vujovic O, Hoy JF, et al.
    A 44-year-old man with an ulcerating skin rash in the setting of advanced human immunodeficiency virus infection.
    AIDS 2021;35:1325-1326.

  15. Lasry A, Baker-Goering M.
    Cost analyses of HIV treatment should be standardized and report cost drivers.
    AIDS 2021;35:1311-1312.

  16. Dash PK, Akay-Espinoza C.
    FDG PET/computed tomography can detect region-specific neuronal changes following antiretroviral therapy in HIV-infected patients.
    AIDS 2021;35:1309-1310.

  17. Dash PK, Boix V.
    Fixed-dose darunavir/cobicistat in pregnancy of HIV-infected women, pharmacokinetic concerns.
    AIDS 2021;35:1301-1303.

  18. Veldsman KA, Laughton B, Janse van Rensburg A, Zuidewind P, et al.
    Viral suppression is associated with HIV-antibody level and HIV-1 DNA detectability in early treated children at 2 years of age.
    AIDS 2021;35:1247-1252.

  19. Imbert E, Hickey MD, Clemenzi-Allen A, Lynch E, et al.
    Evaluation of the POP-UP programme: a multicomponent model of care for people living with HIV with homelessness or unstable housing.
    AIDS 2021;35:1241-1246.

  20. Momper JD, Wang J, Stek A, Shapiro DE, et al.
    Pharmacokinetics of darunavir and cobicistat in pregnant and postpartum women with HIV.
    AIDS 2021;35:1191-1199.

  21. Peng AT, Huang SH, Sun HY, Huang YC, et al.
    Use of dietary supplements containing polyvalent cations and antacids among people living with HIV and its impact on viral suppression.
    AIDS 2021.

  22. Hameiri-Bowen D, Sovershaeva E, Flaegstad T, Gutteberg TJ, et al.
    Soluble biomarkers associated with chronic lung disease in older children and adolescents with perinatal HIV infection.
    AIDS 2021.

  23. Aparicio JM, Xu Y, Li Y, Colantuoni C, et al.
    Plasma microRNAs are associated with domain-specific cognitive function in people with HIV.
    AIDS 2021.

  24. Ogola BO, Matume ND, Mavhandu LG, Tebit DM, et al.
    Drug resistance mutations in a population prior to antiretroviral therapy initiation in Northern South Africa.
    AIDS Res Hum Retroviruses 2021.

  25. Capoferri AA, Redd AD, Gocke CD, Clark LR, et al.
    Persistence of HIV after allogeneic bone marrow transplant in a dually-infected individual.
    AIDS Res Hum Retroviruses 2021.

  26. Hou Z, Tan J, Jiang Y, Zhang L, et al.
    Characterization and Recombinant genotypes of HIV-1 in Gansu Province, China.
    AIDS Res Hum Retroviruses 2021.

  27. .
    Retraction of: Human Immunodeficiency Virus (HIV) and Outcomes from Coronavirus Disease 2019 (COVID-19) Pneumonia: A Meta-Analysis and Meta-Regression (doi: 10.1089/aid.2020.0307).
    AIDS Res Hum Retroviruses 2021;37:503.

  28. de Mendoza C, Caballero E, Eiros JM, Rojo S, et al.
    Impact of COVID-19 on Case Reporting for HTLV and HIV-2 in Spain.
    AIDS Res Hum Retroviruses 2021.

  29. Caleb-Adepoju SO, Dawit R, Gbadamosi SO, Sheehan DM, et al.
    Factors Associated with Viral Suppression among Racial/Ethnic Minority Women in the Miami-Dade County Ryan White Program, 2017.
    AIDS Res Hum Retroviruses 2021.

  30. Olusola FI, Olusola BA, Oladokun R, Falade CO, et al.
    AIDS Res Hum Retroviruses 2021.

  31. Ciccullo A, Baldin G, Borghi V, Lassandro AP, et al.
    Lamivudine plus dolutegravir improves bone mineral density compared to emtricitabine/tenofovir alafenamide plus an integrase inhibitor.
    AIDS Res Hum Retroviruses 2021.

  32. Nguyen DC, Dousa KM, Kurz SG, Brown ST, et al.
    "One-two Punch": Synergistic beta-lactam Combinations for Mycobacterium abscessus and Target Redundancy in the Inhibition of Peptidoglycan Synthesis Enzymes.
    Clin Infect Dis 2021.

  33. Chidambaram V, Tun NL, Majella MG, Ruelas Castillo J, et al.
    Male sex is associated with worse microbiological and clinical outcomes following tuberculosis treatment: A retrospective cohort study, a systematic review of the literature, and meta-analysis.
    Clin Infect Dis 2021.

  34. Schoepf IC, Thorball CW, Ledergerber B, Engel T, et al.
    Coronary Artery Disease-associated and Longevity-associated Polygenic Risk Scores for Prediction of Coronary Artery Disease Events in Persons Living with HIV: The Swiss HIV Cohort Study.
    Clin Infect Dis 2021.

  35. Jacobson MA, Zakaria A, Maung Z, Hart C, et al.
    Incidence and Characteristics of Delayed Injection Site Reaction to the mRNA-1273 SARS-CoV2 Vaccine (Moderna) in a Cohort of Hospital Employees.
    Clin Infect Dis 2021.

  36. Van Gerwen OT, Camino AF, Sharma J, Kissinger PJ, et al.
    Epidemiology, natural history, diagnosis, and treatment of Trichomonas vaginalis in men.
    Clin Infect Dis 2021.

  37. Weiss JJ, Calvi R, Naganawa M, Toyonaga T, et al.
    Preliminary in vivo Evidence of Reduced Synaptic Density in HIV despite Antiretroviral Therapy.
    Clin Infect Dis 2021.

  38. Kuehn BM.
    Community-Based Organizations Step Up to Confront HIV in Southern States.
    JAMA 2021.

  39. Ellsworth GB, Stier EA, Chiao EY, Lensing SY, et al.
    Xpert HPV as a Screening Tool for Anal Histologic High-Grade Squamous Intraepithelial Lesions in Women Living With HIV.
    J Acquir Immune Defic Syndr 2021;87:978-984.

  40. Grande M, Mawandia S, Bakae O, Tau L, et al.
    Intensified Assisted Partner Notification Implementation in Botswana Increased Partner Identification but Not HIV Case-Finding: Findings Highlight the Need for Improved Data Monitoring.
    J Acquir Immune Defic Syndr 2021;87:951-958.

  41. Flynn PM, Taha TE, Cababasay M, Butler K, et al.
    Association of Maternal Viral Load and CD4 Count with Perinatal HIV-1 Transmission Risk during Breastfeeding in the PROMISE Postpartum Component.
    J Acquir Immune Defic Syndr 2021.

  42. Vuylsteke B, Reyniers T, Noestlinger C, Smekens T, et al.
    Can we predict incorrect PrEP use in high HIV risk situations among Men who have Sex with Men? An analysis of Be-PrEP-ared, the Belgian PrEP demonstration study .
    J Acquir Immune Defic Syndr 2021.

  43. Billock RM, Samoff E, Lund JL, Pence BW, et al.
    J Acquir Immune Defic Syndr 2021.

  44. Guzman VA, Cham H, Gutierrez J, Byrd D, et al.
    The Longitudinal Effects of Blood Pressure and Hypertension on Neurocognitive Performance in People Living with HIV.
    J Acquir Immune Defic Syndr 2021.

  45. Amelia de Sousa Mascena Veras, Roza Saggese GS, Gomez Junior JL, Silveira P, et al.
    Young age and sex work are associated with HIV seroconversion among transgender women in Sao Paulo, Brazil.
    J Acquir Immune Defic Syndr 2021.

  46. McMillan JM, Gill MJ, Power C, Fujiwara E, et al.
    Construct and Criterion-Related Validity of the Clinical Frailty Scale in Persons with HIV.
    J Acquir Immune Defic Syndr 2021.

  47. Jasantha O, Kabanda S, Malaba TR, Lesosky M, et al.
    Viral load monitoring in pregnancy to predict peripartum viraemia in South Africa.
    J Acquir Immune Defic Syndr 2021.

  48. Hensen B, Machingura F, Busza J, Birdthistle I, et al.
    How can we support the use of oral PrEP among young women who sell sex? A PrEP cascade analysis.
    J Acquir Immune Defic Syndr 2021.

  49. Dufour C, Gantner P, Fromentin R, Chomont N, et al.
    The multifaceted nature of HIV latency.
    J Clin Invest 2021;131.

  50. Li JZ, Blankson JN.
    How elite controllers and posttreatment controllers inform our search for an HIV-1 cure.
    J Clin Invest 2021;131.

  51. Rosenberg ES, Tesoriero JM.
    A Tale of Many New York Cities.
    J Infect Dis 2021.

  52. Ragonnet-Cronin M, Golubchik T, Moyo S, Fraser C, et al.
    HIV genetic diversity informs stage of HIV-1 infection among patients receiving antiretroviral therapy in Botswana.
    J Infect Dis 2021.

  53. Kinloch NN, Ritchie G, Brumme CJ, Dong W, et al.
    Corrigendum to: Suboptimal Biological Sampling as a Probable Cause of False-Negative COVID-19 Diagnostic Test Results.
    J Infect Dis 2021.

  54. Wanaguru M, Bishop KN.
    HIV-1 Gag recruits oligomeric Vpr via two binding sites in p6, but both mature p6 and Vpr are rapidly lost upon target cell entry.
    J Virol 2021.

  55. Priceputu E, Cool M, Bouchard N, Caceres-Cortes JR, et al.
    HIV-1 Nef induces Hck/Lyn-dependent expansion of MDSC associated with elevated IL-17/G-CSF.
    J Virol 2021.

  56. Davids BO, Balasubramaniam M, Sapp N, Prakash P, et al.
    Human Three Prime Repair Exonuclease 1 Promotes HIV-1 Integration by Preferentially Degrading Unprocessed Viral DNA.
    J Virol 2021.

  57. van Haaren MM, McCoy LE, Torres JL, Lee W, et al.
    Antibodies from rabbits immunized with HIV-1 clade B SOSIP trimers can neutralize multiple clade B viruses by destabilizing the envelope glycoprotein.
    J Virol 2021.

  58. Alsulami K, Bolastig N, Dupuy FP, Mabanga T, et al.
    Influence of NKG2C Genotypes on HIV Susceptibility and Viral Load Set Point.
    J Virol 2021.

  59. Qin K, Boppana S, Carlson JM, Fiore-Gartland A, et al.
    Elevated HIV infection of CD4 T cells in MRKAd5 vaccine recipients due to CD8 T cells targeting of adapted epitopes.
    J Virol 2021.

  60. Luo MT, Mu D, Yang X, Luo RH, et al.
    Tree shrew cells transduced with human CD4 and CCR5 support early steps of HIV-1 replication, but viral infectivity is restricted by APOBEC3.
    J Virol 2021.

  61. Nakajima S, Watashi K, Kato T, Muramatsu M, et al.
    Biochemical and structural properties of entecavir-resistant hepatitis B virus polymerase with L180M/M204V mutations.
    J Virol 2021.

  62. Kuse N, Akahoshi T, Takiguchi M.
    STING ligand-mediated priming of functional CD8(+) T-cells specific for HIV-1 protective epitopes from naive T-cells.
    J Virol 2021.

  63. Beyrer C.
    A pandemic anniversary: 40 years of HIV/AIDS.
    Lancet 2021;397:2142-2143.

  64. Samarasekera U.
    40 years of HIV/AIDS: an interview with Peter Piot.
    Lancet 2021;397:2138-2139.

  65. Cornell M, Majola M, Johnson LF, Dubula-Majola V, et al.
    HIV services in sub-Saharan Africa: the greatest gap is men.
    Lancet 2021;397:2130-2132.

  66. The Lancet.
    40 years of HIV/AIDS: a painful anniversary.
    Lancet 2021;397:2125.

  67. Makoni M.
    Africa's need for more COVID-19 clinical trials.
    Lancet 2021;397:2037.

  68. Dharan NJ, Yeh P, Bloch M, Yeung MM, et al.
    HIV is associated with an increased risk of age-related clonal hematopoiesis among older adults.
    Nat Med 2021.

  69. Saag MS.
    HIV Infection - Screening, Diagnosis, and Treatment.
    N Engl J Med 2021;384:2131-2143.

  70. Ronge L, Sloot R, Du Preez K, Kay AW, et al.
    The Magnitude of Interferon Gamma Release Assay Responses in Children With Household Tuberculosis Contact Is Associated With Tuberculosis Exposure and Disease Status.
    Pediatr Infect Dis J 2021.

Display articles in

Amedeo HIV Infection

Data Origin

You selected the following journals for your Amedeo HIV Infection newsletter:

AIDS, AIDS Res Hum Retroviruses, Ann Intern Med, BMJ, Clin Infect Dis, J Acquir Immune Defic Syndr, J Clin Immunol, J Clin Invest, J Infect Dis, J Med Virol, J Virol, JAMA, Lancet, N Engl J Med, Nat Med, Pediatr Infect Dis J, Science, Virology.

To modify the journal selection, please open your Newsletter Management Page. If you don't remember the URL, please submit the email address of your Amedeo subscription.

Your email:

Amedeo HIV Infection

Five-Week Literature

26 July 2021

19 July 2021

12 July 2021

05 July 2021

28 June 2021

14 June 2021

Multidisciplinary Journal Club

  1. Radonovich LJ Jr, Simberkoff MS, Bessesen MT, Brown AC, et al.
    N95 Respirators vs Medical Masks for Preventing Influenza Among Health Care Personnel: A Randomized Clinical Trial.
    JAMA. 2019;322:824-833.

  2. Deng L, Chang TZ, Wang Y, Li S, et al.
    Heterosubtypic influenza protection elicited by double-layered polypeptide nanoparticles in mice.
    Proc Natl Acad Sci U S A. 2018 Jul 31. pii: 1805713115.

  3. Walker TA, Waite B, Thompson MG, McArthur C, et al.
    Risk of Severe Influenza among Adults with Chronic Medical Conditions.
    J Infect Dis. 2019 Nov 4. pii: 5611323. doi: 10.1093.

Every week, Amedeo's Multidisciplinary Journal Club (MJC) presents a selection of outstanding articles. Take a look beyond the horizon.

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016